Skip to main content
. Author manuscript; available in PMC: 2025 Jul 6.
Published in final edited form as: Clin Cancer Res. 2025 Jan 6;31(1):12–17. doi: 10.1158/1078-0432.CCR-24-2196

Table 2:

Efficacy Results in Patients with IDH1-Mutated R/R AML on Study 2102-HEM-101

Endpoint Olutasidenib (150mg BID), N=147
CR + CRh, n (%) 51 (35)
 95% CI (27,43)
 Median DOCR + CRh (months) 25.9
 95% CI (13.5, NR)
CR, n (%) 47 (32)
 95% CI (25,40)
 Median DOCR (months) 28.1
 95% CI (13.8, NR)
CRh, n (%) 4 (2.7)
 95% CI (4.5,13.1)
 Median DOCRh (months) 3.6
 95% CI (1,5.5)
Conversion from TD to TI, n (%) 29/86 (34%)
Maintenance of TI, n (%) 39/61 (64%)

Source: FDA Data